|
Characteristics at ART initiation |
Summary |
| Gender |
|
| Male, n (%) |
262 (33.5%) |
| Female, n (%) |
520 (66.5%) |
| Age (years), median (IQR) |
36 (31-43) |
| Baseline CD4 count (cells/mm3), median (IQR) |
115 (64-183) |
| CD4 count < 200 cells/mm3, n (%) |
624 (82.3%) |
| CD4 count ≥ 200 cells/mm3, n (%) |
134 (17.7%) |
| Baseline weight (kg), median (IQR) |
62 (55-70) |
| Baseline weight < 60kg, n (%) |
305 (40.8%) |
| Baseline weight ≥ 60kg, n (%) |
442 (59.2%) |
| WHO stage |
|
| WHO stage IV, n (%) |
186 (25.4%) |
| WHO stage I/II/III, n (%) |
545 (74.6%) |
| Initial first line ART regimen |
|
| NVP-3TC-d4T, n (%) |
282 (36.1%) |
| NVP-3TC-AZT, n (%) |
296 (37.9%) |
| EFV-3TC-d4T, n (%) |
38 (4.9%) |
| EFV-3TC-AZT, n (%) |
153 (19.6%) |
| Other, n (%) |
13 (0.7%) |
IQR – interquartile range; ART –antiretroviral therapy; NVP – Nevirapine; EFV –
Efavirenz; 3TC – Lamuvidine; d4T – Stavudine; AZT – Zidovudine; Missing values:
Weight (n=35), WHO stage (n=51); CD4 count (n=24); all other covariates (n=0). |
